Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEland Oil & Gas Regulatory News (ELA)

  • There is currently no data for ELA

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Renee P. Tannenbaum, Pharm.D. Joins Elan as Executive Vice President and Chief Commercial Officer

29 May 2009 14:00

Elan Corporation, plc (NYSE: ELN) announced today that Renee P. Tannenbaum, Pharm.D., has joined the company as Executive Vice President and Chief Commercial Officer. Dr. Tannenbaum will be based at Elan's South San Francisco campus and report to Elan President Carlos Paya, MD, PhD.

Elan CEO Kelly Martin said that Dr. Tannenbaum was joining the company at a special time, as Elan establishes itself as one of only a few companies to successfully integrate a robust biotechnology pipeline and comprehensive commercial capabilities. "To be successful in the commercial arena," Mr. Martin said, "we need a leader with significant expertise in product launches, sales, marketing, managed markets, product development and commercialization, alliance management and leadership development. Of all the candidates we spoke with, Dr. Tannenbaum was unique in bringing demonstrated strengths in all these areas to the table."

Dr. Tannenbaum will be responsible for ensuring that Elan delivers on the revenue expectations for its marketed products, particularly Tysabri; preparing for the commercialization of the company's pipeline, including its Alzheimer's portfolio; and strengthening the company's overall commercial capabilities and commitment to strong performance. Elan's Commercial Operations, Strategic Brand Management and Commercial Strategy teams will report to Dr. Tannenbaum, and she will become a member of the BioPharma Leadership Team, headed by Dr. Paya.

Dr. Paya said that the company planned for the role of a Chief Commercial Officer to grow and lead Elan's commercial capabilities for some time. "Dr. Tannenbaum's experience, strategic perspective and specific commercial expertise-both in the U.S. and internationally-precisely meet Elan's needs today and moving forward," Dr. Paya said. "Her new role reflects an enhanced level of responsibility for ensuring our commercial opportunities are fully realized."

Dr. Tannenbaum joins Elan with more than 25 years of global pharmaceutical experience, most recently as Head of Global Commercial Operations for Novartis Pharma AG, a role she had held since joining the company three years ago.

Previously, Dr. Tannenbaum was with Bristol-Myers Squibb for nine years, in a range of executive commercial positions with increasing management and revenue-generation responsibility. These included: Vice President, Convatec, Americas; Vice President, Healthcare Channel Management, U.S. Pharmaceuticals; Regional Vice President of Sales, U.S. Primary Care; Vice President, Marketing, Avapro and Avalide; and Vice President, Marketing and Sales Force Effectiveness, Worldwide Medicines Group.

Earlier in her career, Dr. Tannenbaum was with Merck-Medco Managed Care for three years, preceded by 10 years at Merck & Co., with positions of increasing responsibility in marketing, market research, managed care, sales and clinical research. She is also Adjunct Clinical Assistant Professor at Philadelphia College of Pharmacy & Sciences, a division of University of the Sciences in Philadelphia (since 1981).

About Elan

Elan Corporation, plc is a neuroscience-based biotechnology company committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. Elan shares trade on the New York, London and Dublin Stock Exchanges. For additional information about the company, please visit http://www.elan.com.

CONTACT: Elan Corporation, plc
Investors:
Chris Burns, 800-252-3526
David Marshall, 353-1-709-4403
or
Media:
Mary Stutts, 650-794-4403
Niamh Lyons, 353-1-553-3602

Copyright Business Wire 2009

Date   Source Headline
2nd Jan 20157:00 amRNSAppointment of Non-Executive Director
18th Dec 20147:00 amRNSDirector/PDMR Shareholding
17th Dec 20147:00 amRNSCrude Oil Sale Update
5th Dec 20147:00 amRNSAccess to US$22 million Loan Facility
1st Dec 20146:24 pmRNSTR-1: Notification of Major Interest in Shares
1st Dec 20145:34 pmRNSHenderson Global Investors
26th Nov 20141:34 pmRNSTR-1: Notification of Major Interest in Shares
26th Nov 20141:26 pmRNSTR-1: Notification of Major Interest in Shares
24th Nov 20143:50 pmRNSTR-1:Notification of major interest in shares
24th Nov 20143:47 pmRNSTR-1: Notification of major interest in shares
24th Nov 20147:00 amRNSOperations and Financing Update
18th Nov 20142:51 pmRNSExercise of Options
11th Nov 20145:25 pmRNSNotification of Major Interest in Shares
13th Oct 20145:31 pmRNSNotification of Major Interest in Shares
8th Oct 20147:00 amRNSNew CPR and Operational Update
15th Sep 20147:00 amRNSDirectorate Changes
11th Sep 20144:23 pmRNSTR-1: Notification of Major Interest in Shares
8th Sep 20147:00 amRNSBoard Changes
4th Sep 20147:00 amRNSOperations Update
15th Aug 20147:01 amRNSAcquisition of 40% interest in the Ubima Field
15th Aug 20147:00 amRNSInterim results for the six months to 30 June 2014
5th Aug 20145:55 pmRNSTR-1: Notification of Major Interest in Shares
11th Jul 20147:00 amRNSCorrection: TR-1 Notification
9th Jul 20141:25 pmRNSTR-1: Notification of Major Interest in Shares
7th Jul 20145:05 pmRNSTR-1: Notification of Major Interest in Shares
3rd Jul 20147:00 amRNSTR-1: Notification of Major Interest in Shares
30th Jun 20147:00 amRNSFiscal Status Update
20th Jun 20142:26 pmRNSResult of AGM
4th Jun 20147:00 amRNSDirectors Dealings
29th May 201411:02 amRNSPosting of Annual Report and Notice of AGM
27th May 20147:00 amRNSFinal Results
9th May 20149:53 amRNSTR-1: Notification of Major Interest in Shares
9th May 20149:51 amRNSTR-1: Notification of Major Interest in Shares
8th May 201411:15 amRNSTR-1: Notification of Major Interest in Shares
7th May 20149:23 amRNSTR-1: Notification of Major Interest in Shares
30th Apr 20142:41 pmRNSExercise of Options
22nd Apr 20144:39 pmRNSTR-1: Notification of Major Interest in Shares
9th Apr 20147:00 amRNSTR-1: Notification of Major Interest in Shares
26th Mar 20142:04 pmRNSExercise of Options to raise £14m
21st Mar 201410:03 amRNSTR-1: Notification of Major Interest in Shares
19th Mar 20144:56 pmRNSTR-1: Notification of Major Interest in Shares
19th Mar 201411:23 amRNSTR-1: Notification of Major Interest in Shares
17th Mar 20144:48 pmRNSTR-1: Notification of Major Interest in Shares
14th Mar 201412:33 pmRNSTR-1: Notification of Major Interest in Shares
13th Mar 20147:00 amRNSFiscal Status Update & Exercise of Options
7th Mar 20144:45 pmRNSTR-1: Notification of Major Interest in Shares
5th Mar 20149:07 amRNSTR-1: Notification of Major Interest in Shares
3rd Mar 20143:35 pmRNSTR-1: Notification of Major Interest in Shares
27th Feb 20147:00 amRNSExtension of Loan Facility & Exercise of Options
24th Feb 20142:52 pmRNSTR-1: Notification of Major Interest in Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.